SCHEMBL14839422

SCHEMBL14839422

Cn1ccc(Nc2ccc(Br)cn2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
LMNA P02545 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
LRRK2 Q5S007 1/20 0.41
MAPK1 P28482 2/20 0.41
PIK3CA P42336 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
KCNH2 Q12809 1/20 0.38
SYK P43405 1/20 0.38
GCK P35557 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
FDPS P14324 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RAB9A P51151 2/20 0.37
MAP4K1 Q92918 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15688182 0.80 LRRK2 (0.44) ALDH1A1LMNALRRK2MAPK1PIK3CA
SCHEMBL355054 0.80 ALDH1A1 (0.50) ALDH1A1LMNAMAPK1RXFP1FDPS
SCHEMBL2657070 0.78 HPGDS (0.45) ALDH1A1LRRK2MAPK1PIK3CAMAPK8
SCHEMBL14839431 0.77 ALDH1A1 (0.41) ALDH1A1LMNACYP1A2CYP2C19MAPK1
SCHEMBL3091753 0.75 MAPK1 (0.48) LRRK2MAPK1PIK3CAMAPK8MAPK9
SCHEMBL2657982 0.73 CYP19A1 (0.47) ALDH1A1LMNALRRK2MAPK1PIK3CA
SCHEMBL15688438 0.72 KMT2A (0.50) ALDH1A1LMNALRRK2MAPK10GCK
SCHEMBL181171 0.72 LRRK2 (0.40) ALDH1A1LMNALRRK2MAPK1PIK3CA
SCHEMBL2669643 0.72 CYP19A1 (0.40) LRRK2MAPK1PIK3CAMAPK8MAPK9
SCHEMBL2657999 0.72 MAPK1 (0.38) LRRK2MAPK1PIK3CAMAPK8MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9359344-B2 Biaryl heterocycle substituted oxazolidinone antibacterial agents Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
US-9359344-B2 Biaryl heterocycle substituted oxazolidinone antibacterial agents Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
US-9359344-B2 Biaryl heterocycle substituted oxazolidinone antibacterial agents Xuanzhu Pharma Co., Ltd. (CN) 2016-06-07 US disclosed
US-20140235584-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS Xuanzhu Pharma Co., Ltd. (CN) 2014-08-21 US disclosed
US-20140235584-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS Xuanzhu Pharma Co., Ltd. (CN) 2014-08-21 US disclosed
US-20140235584-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS Xuanzhu Pharma Co., Ltd. (CN) 2014-08-21 US disclosed
EP-2762479-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG Xuanzhu Pharma Co., Ltd. (CN) 2014-08-06 EP disclosed
WO-2013044845-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG 山东轩竹医药科技有限公司 (CN) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235584-A1 BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS OXA1L, CYP2C19, CBR3 ALDH1A1 721/4885LMNA 3145/4885CYP1A2 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.